The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
You Are the Hope
Hope is an important resource during difficulty times. Mary Garland, Director of Communications for the LRG, shares her observations on hope.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
OVAC 2020 Virtual Lobby Day
May 19, 2020 is OVAC Lobby Day highlights its work delivering a unified message to Congress and the White House on the need for increased cancer-related appropriations. Held virtually this year due to the COVID-19 pandemic, these requests affect millions of Americans facing cancer each day.
Patient of the Month for June: John Garuti Jr.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. John Garuti Jr. shares his story.
Estado de los tratamientos GIST
Medicamentos actuales y emergentes “Existen muchas opciones terapéuticas disponibles, pero sigue siendo un desafío hacer coincidir el medicamento correcto con el [...]
The Trauma of Cancer & Pandemics
Cancer and COVID both leave us feeling so out of control. Grief expert Claire M. Schwartz shares her thoughts on the similarities of the trauma of cancer & pandemics and offers some advice on coping.
Dr. George D. Demetri Receives the 2020 David A. Karnofsky Memorial Award
As posted in the ASCO Daily News, Dr. George Demetri, has received recognition for his work in developing targeted TKIs for GIST.
GLOBAL PARTNERS & AFFILIATIONS
